Introduction
The identification of the cyclic GMP/NO pathway as the final neurotransmitter messengers responsible for penile erection and the subsequent development of highly specific phosphodiesterase enzyme inhibitors has revolutionised the treatment of erectile dysfunction. Sildenafil citrate and tadalafil citrate are effective, well tolerated and safe treatments for erectile dysfunction caused by a broad range of aetiologies. 1, 2 Priapism for longer than 6 h is a recognised complication of intracavernous injection therapy and have been reported to occur in 0.25% of men using alprostadil monotherapy and 0.9% of men using combination pharmacotherapy containing alprostadil, papaverine and phentolamine. 3, 4 An extensive review of the published medical literature and the manufacturer's clinical trial and postmarketing database identified six reports of priapism following the use of sildenafil in an estimated 1.2 billion users. [5] [6] [7] [8] Several authors have reported that 15-25% of men previously treated with intracavernous injection therapy who respond to sildenafil will choose to alternate between both forms of therapy according to circumstance. 9, 10 Combination therapy using sildenafil and intracavernous combination pharmacotherapy have been reported to salvage 30% of men refractory to either treatment alone. 11 We report three cases of priapism occurring in men following intracavernous self-administration of vasoactive drugs following administration of a phosphodiesterase inhibitor drug.
Case 1
A 46-year-old man with type II diabetes, hypertension and dyslipidaemia and a 4-year history of erectile dysfunction, presented with a painful priapism 7 h following the administration of oral sildenafil (100 mg) and the subsequent intracavernous administration of alprostadil (15 mg). Corporal aspiration of dark deoxygenated blood confirmed the presence of a low flow ischaemic priapism. The patient had recently been prescribed sildenafil by his local medical officer and had failed to achieve an erection sufficient for penetration on each of the three occasions when he attempted intercourse approximately 10 min after ingestion of the drug. On the third administration, he administered an intracavernous injection of alprostadil approximately 1 h after ingestion of sildenafil. His priapism subsided after serial corporal aspiration and irrigation with dilute phenylephrine. Subsequent penile duplex Doppler ultrasonography did not demonstrate any postpriapism corporal fibrosis. Following dose titration and re-education, he now responds well to sildenafil and no longer uses intracavernous injection therapy.
Case 2
A 53-year-old man with a 2-year history of vasculogenic erectile dysfunction, initially diagnosed with colour duplex Doppler ultrasonography, presented with a painful 10 h priapism following the initial administration of sildenafil (100 mg) and the subsequent intracavernous administration of Trimix (0.25 ml.) A low flow ischaemic priapism was confirmed by the absence of cavernous artery blood flow on colour duplex Doppler ultrasonography and the presence of deoxygenated blood on corporal aspiration. He had been treated successfully with sildenafil since his initial presentation, but had administered Trimix prescribed to his male sexual partner 1.5 h after administration of sildenafil to augment his erection. Serial corporal aspiration and irrigation with dilute phenylephrine resulted in detumescence within 45 min. Subsequent penile duplex Doppler ultrasonography did not demonstrate any postpriapism corporal fibrosis.
Case 3
A 37-year-old man with long-standing psychogenic erectile dysfunction confirmed by Rigiscan NPT presented with a 14 h episode of priapism. He had been previously treated with psychosexual therapy and responded well with alternating use of intracavernous injection therapy using Trimix and sildenafil. He had recently been prescribed and responded well to tadalafil (20 mg). Approximately 18 h after administration of tadalafil (20 mg), he administered an intracavernous injection of Trimix (0.25 ml) and developed a subsequent priapism. The absence of cavernous artery blood flow on colour duplex Doppler ultrasonography and corporal aspiration of deoxygenated blood confirmed the presence of an ischaemic priapism. He was treated with serial corporal aspiration and irrigation with dilute phenylephrine and detumesced within 90 min.
Discussion
The medical literature contains six cases of sildenafil-induced priapism. Sur and Kane 5 reported a 24-h priapism following sildenafil (100 mg) in a 28-year-old man and Aoyaji et al 6 reported persistent priapism in a 53-year-old man following administration of sildenafil (200 mg) 3 days earlier. Kassim et al 7 reported a case of priapism in a 39-year-old male with sickle cell trait. Goldmeier and Lamba 8 reported two cases of priapism following the co-administration of sildenafil and dihydrocodeine, and suggested that acute opiate intake produced abnormally high cyclic-GMP levels in peripheral nerve endings and an augmented response to sildenafil. Yoon et al 12 reported a single case of priapism following intracavernous injection of sildenafil citrate. All cases were managed conservatively and detumescence was achieved.
Although the majority of patients choose monotherapy treatment with an oral PDE-5 inhibitor, a significant number of patients for reasons of personal preference, convenience, speed of onset of erectile response and cost, continue to use injection therapy intracavernous intermittently. 9 It is incumbent on the treating physician to ensure that patients understand the expected duration of action of PDE-5 inhibitors and are aware of the potential for priapism if intracavernous injection therapy is administered at either the same time or within that period of time. This is of particular importance with tadalafil due to its relatively long half-life of 17.5 h.
